Brief: Eqrx Announces Acceptance Of Marketing Authorization Application By The European Medicines Agency For Aumolertinib In Egfr-Mutated Non-Small Cell Lung Cancer
02/12/2022 13:26
Dec 2 (Reuters) -
* EQRX ANNOUNCES ACCEPTANCE OF MARKETING AUTHORIZATION
APPLICATION
BY THE EUROPEAN MEDICINES AGENCY FOR AUMOLERTINIB IN
EGFR-MUTATED NON-SMALL CELL LUNG CANCER
Source text for Eikon: ID:nGNX1hZNRW
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on EQRx
See all newsBrief: Leading Independent Proxy Advisory Firms ISS And Glass Lewis Recommend Revolution Medicines Stockholders Vote "FOR" Proposed Acquisition Of EQRx, Inc
Brief: Revolution Medicines Inc Says Will Acquire EQRx In An All-Stock Transaction
U.S. RESEARCH ROUNDUP- Cigna Group, McKesson, Zscaler
Brief: EQRx posts Q1 EPS USD -0.17
Brief: EQRx Says Jami Rubin Will Step Down As Chief Financial Officer